

1. PRODUCT AND COMPANY INFORMATION


Distributed By: WG Critical Care, LLC.
120 Route 17 North
Suite 115
Paramus, NJ 07652 USA

Product Name: **Cefazolin for Injection, USP**

Product Code: 500mg Vial: 44567-706-25
1g Vial: 44567-707-25
10g Vial: 44567-708-10
20g Vial: 44567-709-10

Common / Trade Name: Cefazolin for Injection, USP

Structure:



Chemical Name: (1) 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[[[5-methyl-1,3,4-thiadiazol-2-yl]thio]methyl]-8-oxo-7-[[[(1H-tetrazol-1-yl)acetyl]amino]-, monosodium salt (6R-trans)-; (2) Monosodium (6R,7R)-3-[[[5-methyl-1,3,4-thiadiazol-2-yl]thio]methyl]-8-oxo-7-[2-(1H-tetrazol-1-yl)acetamido]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (3) 3-[[[5-Methyl-1,3,4-thiadiazol-2-yl]thio]methyl]-7-[2-(1H-tetrazol-1-yl)acetamido]-3-cephem-4-carboxylate

Molecular Formula: C₁₄H₁₃N₈NaO₄S₃
UNII Code: UNII-P380M0454Z
CAS Number: 27164-46-1
Chemical Family: Antibacterial (systemic)
Product Use: Pharmaceutical
Product Type: Prescription Drug

Container Information: Vials

WG Critical Care, LLC.

Cefazolin for Injection, USP	Material Safety Data Sheet (MSDS)	
Version: 1.4	Issue Date: 5 August 2013	Page 1 of 6



1. PRODUCT AND COMPANY INFORMATION (CONT.)

General Phone Number: +1-847-549-3200
Customer Service Phone Number: +1-888-493-0861
Emergency Phone Number: +1-866-562-4708 (Prosar)

2. COMPOSITION / INFORMATION ON INGREDIENTS

<u>Ingredient</u>	<u>Weight %</u>	<u>CAS No.</u>
Cefazolin Sodium	100	27164-46-1

3. HAZARDS IDENTIFICATION

PRIMARY PHYSICAL AND HEALTH HAZARDS: May cause irritation to eyes, skin, and respiratory tract. Product may cause allergic reaction if inhaled or absorbed through the skin.

ROUTES OF ENTRY: Eyes, skin, inhalation.

SIGNS & SYMPTOMS OF EXPOSURE: Exposure can cause dilation of the blood vessels and an increase in contraction of some smooth muscles.

CHEMICAL LISTED AS CARCINOGEN: **NTP:** NO **IARC:** NO **OSHA:** NO

4. FIRST AID MEASURES

EYE EXPOSURE: Flush eyes with water for 10-20 minutes. Seek medical attention.
SKIN EXPOSURE: Remove contaminated clothing wash skin for 15-20 minutes with soap and water. Seek medical attention.
INGESTION: Do NOT induce vomiting. Flush mouth with water and seek medical attention immediately.
INHALATION: If there is breathing difficulty, remove from exposure and administer oxygen. See medical attention immediately.
NOTE TO PHYSICIAN: See patient package insert in shipping carton for complete information.

WG Critical Care, LLC.

Cefazolin for Injection, USP	Material Safety Data Sheet (MSDS)	
Version: 1.4	Issue Date: 5 August 2013	Page 2 of 6



5. FIRE FIGHTING MEASURES

FLASH POINT:	Not established
AUTO-IGNITION TEMPERATURE:	Not established
FLAMMABLE LIMITS IN AIR:	Not established
FLAMMABLE LIMITS:	Not established
EXTINGUISHING MEDIA:	Water, dry chemical or foam.
UNUSUAL FIRE / EXPLOSION HAZARDS:	Not determined

6. ACCIDENTAL RELEASE MEASURE

SPILL:	Contain and collect spillage and place in container for disposal according to local regulations (See Section 13). Wipe surface area clean with soap and water. Avoid contact with strong oxidizing agents.
RELEASE TO AIR:	Prevent release to environment. If aerosolized reduce exposure by ventilating area.
RELEASE TO WATER:	Refer to local water authority. Drain disposal is not recommended; refer to local, state, and federal disposal guidelines.

7. HANDLING AND STORAGE

GENERAL HANDLING:	When handling pharmaceutical products, avoid all contact and inhalation of dust, fumes, mist, and/or vapors associated with the product. Keep away from sources of ignition.
STORAGE CONDITIONS:	Keep containers tightly closed in a cool, well-ventilated place. Store at room temperature between 20°C and 25°C (68°F and 77°F).

WG Critical Care, LLC.

Cefazolin for Injection, USP	Material Safety Data Sheet (MSDS)	
Version: 1.4	Issue Date: 5 August 2013	Page 3 of 6



8. EXPOSURE CONTROLS / PERSONAL PROTECTION

RESPIRATORY PROTECTION:	If aerosols are generated, a disposable dust/mist respirator (N95) may be used. Personnel wearing respirators should be fit tested and approved for respirator use under the OSHA Respiratory Protection Standard 29 CFR 1910.134.
EYE PROTECTION:	Chemical goggles and/or face shield. Safety glasses are always required.
VENTILATION:	Laboratory fume hood or local exhaust ventilation.
SKIN PROTECTION:	Work uniform or laboratory coat.
OTHER PROTECTIVE EQUIPMENT:	Protective Latex or Nitrile gloves
ADDITIONAL EXPOSURE PRECAUTIONS:	In production settings, airline-supplied, hood-type respirators are preferred. Shower and change clothing if skin contact occurs.

9. PHYSICAL AND CHEMICAL PROPERTIES

PHYSICAL STATE:	Solid -	SPECIFIC GRAVITY:	Equivalent to water
APPEARANCE AND ODOR:	White to off-white lyophilized powder	EVAPORATION RATE:	Equivalent to water
BOILING POINT:	Not determined	MELTING POINT:	198-200°C
VAPOR PRESSURE:	Not determined	SOLUBILITY IN WATER:	Soluble in water
VAPOR DENSITY:	Not determined	pH:	4.5-6.0

10. STABILITY AND REACTIVITY

STABILITY:	Store in a cool and ventilated place at the temperature of 25°C ± 2°C. Avoid exposure to heat sources also localized.
INCOMPATIBILITY : (MATERIALS TO AVOID)	Strong oxidizing agents
HAZARDOUS POLYMERIZATION:	Will not occur
HAZARDOUS DECOMPOSITION:	When heated to decomposition material, it emits toxic fumes of sulfur oxide gases (SOx), nitrogen oxides(NOx) and sodium oxide (Na ₂ O)(6).
CONDITIONS TO AVOID:	Protect from moisture. Avoid accumulation of electronstatic charge. Keep away from open flames, heat and direct lighting.

WG Critical Care, LLC.

Cefazolin for Injection, USP	Material Safety Data Sheet (MSDS)	
Version: 1.4	Issue Date: 5 August 2013	Page 4 of 6



11. TOXICOLOGICAL INFORMATION

ACUTE TOXICITY

COMPONENT	TYPE	ROUTE	SPECIES	DOSAGE
Cefazolin Sodium	LD ₅₀	IV	Rat	2760mg/kg

12. ECOLOGICAL INFORMATION

Not established

13. DISPOSAL CONSIDERATIONS

WASTE DISPOSAL: Dispose of any cleanup materials and waste products according to all local, state, and federal laws and regulations.

14. TRANSPORT INFORMATION

REGULATORY ORGANIZATIONS:

DOT: Not Regulated

ICAO / IATA: Not Regulated

IMO: Not Regulated

15. REGULATORY INFORMATION

Below is selected regulatory information chosen primarily for possible WG Critical Care use. This section is not a complete analysis or reference to all applicable regulatory information. Please consider all applicable laws and regulations for your city / state / country.

US Regulations

TSCA – No

CERCLA-No

SARA 302 – No

SARA 313 – No

OSHA Substance Specific - No

WG Critical Care, LLC.

Cefazolin for Injection, USP	Material Safety Data Sheet (MSDS)		
Version: 1.4	Issue Date: 5 August 2013	Page 5 of 6	



16. OTHER INFORMATION

As of the date of issuance, we are providing available information relevant to the handling of this material in the workplace. All information contained herein is offered with the good faith belief that it is accurate. THIS MATERIAL SAFETY DATA SHEET SHALL NOT BE DEEMED TO CREATE ANY WARRANTY OF ANY KIND (INCLUDING WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE). In the event of an adverse incident associated with this material, this safety data sheet is not intended to be a substitute for consultation with appropriately trained personnel. Nor is this safety data sheet intended to be a substitute for product literature which may accompany the finished product.

WG Critical Care, LLC.

Cefazolin for Injection, USP	Material Safety Data Sheet (MSDS)	
Version: 1.4	Issue Date: 5 August 2013	Page 6 of 6